A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...
News Medical on MSN
Study tests combined targeted radiopharmaceuticals and precision radiation for recurrent prostate cancer
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether combining precision radiation with a targeted radioactive therapy drug can ...
For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before the cancer comes back. Researchers at UCLA have found that a blend of a ...
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether combining precision radiation with a targeted radioactive therapy drug can ...
Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...
MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 ...
Advanced imaging, particularly PSMA PET scans, enhances detection of microscopic disease, allowing for more precise treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results